Company profile
Syndax Pharmaceuticals Inc
NASDAQ:SNDXBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Revumenib Citrate | approved | — | 0 | — |
| AXATILIMAB | phase2 | — | 1 | terminated |
| ENTINOSTAT | phase1 | — | 1 | terminated |
| Revumenib sesquifumarate | phase1 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (29)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03238027 | phase1 | completed | 2017-09-01 | 2020-11-20 | Syndax Pharmaceuticals | A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors |
| NCT03604692 | phase1_2 | completed | 2018-11-01 | 2022-08-12 | Syndax Pharmaceuticals | A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD |
| NCT00750698 | phase2 | terminated | 2008-08-01 | 2010-05-01 | Syndax Pharmaceuticals | A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib |
| NCT00866333 | phase2 | terminated | 2009-04-13 | 2013-02-08 | Syndax Pharmaceuticals | A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma |
| NCT04415073 | phase2 | terminated | 2020-05-30 | 2020-07-13 | Syndax Pharmaceuticals | A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 218944 | NDA | SYNDAX PHARMACEUTICALS INC | ||||
Loading… | ||||||